marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-14-2024
Lineage Cell Therapeutics Financial Ratios 2011-2024 | LCTX
Annual Financial Ratios Lineage Cell Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-40.1 | -38.2 | -8.0 | -16.1 | -13.3 | -3.9 | -17.0 | 8.8 | -4.1 | -7.4 | -4.8 | -10.4 | -16.9 |
P/S |
91.8 | 126.8 | 198.6 | 181.5 | 44.3 | 36.1 | 98.0 | 49.6 | 27.4 | 51.7 | 47.1 | 56.8 | 64.1 |
EPS |
-0.0 | -0.0 | -0.2 | -0.1 | -0.1 | -0.4 | -0.2 | 0.3 | -0.6 | -0.6 | -0.8 | -0.4 | -0.3 |
EV (Enterprise Value) |
195 M | 283 M | 260 M | 312 M | 160 M | 166 M | 311 M | 284 M | 169 M | 254 M | 219 M | 224 M | 261 M |
EBITDA per Share |
-0.03 | -0.04 | -0.17 | -0.162 | -0.246 | -0.297 | -0.326 | -0.557 | -0.746 | -0.636 | -0.638 | -0.45 | -0.344 |
EV/EBITDA |
-0.6 | -12.3 | -4.1 | -4.2 | -8.1 | -5.1 | -2.5 | -5.7 | -5.9 | -9.8 | -15.7 | ||
PEG |
1.36 | 1.45 | 0.41 | -0.21 | 0.17 | -0.04 | 0.11 | -0.05 | -0.56 | 0.23 | -0.06 | -0.4 | -0.68 |
P/B |
3.1 | 3.4 | 2.6 | 3.5 | 1.4 | 2.0 | 2.1 | 2.3 | 2.5 | 4.3 | 4.9 | 9.2 | 6.7 |
P/CF |
-6.7 | 229.3 | -9.8 | -16.7 | -4.8 | -5.3 | -10.6 | -6.6 | -3.9 | -6.9 | -6.6 | -11.1 | -19.2 |
ROE % |
-7.53 | -8.66 | -31.44 | -21.71 | -10.53 | -49.86 | -12.16 | 25.72 | -61.47 | -58.05 | -103.83 | -88.19 | -39.84 |
ROA % |
-4.73 | -5.14 | -16.61 | -19.13 | -9.33 | -45.24 | -11.53 | 23.55 | -49.64 | -48.61 | -76.01 | -72.02 | -36.04 |
ROCE % |
-10.03 | -9.05 | -30.62 | -26.40 | -32.67 | -43.22 | -24.44 | -44.10 | -80.06 | -74.78 | -75.88 | -98.59 | -43.78 |
Current Ratio |
2.6 | 2.4 | 2.1 | 5.7 | 8.9 | 5.3 | 6.2 | 2.9 | 3.8 | 4.5 | 1.1 | 1.6 | 7.9 |
DSO |
91.1 | 4854.3 | 7912.5 | 0.8 | 2485.9 | 272.1 | 321.5 | 71.3 | 85.3 | 98.8 | - | - | - |
DIO |
- | - | - | - | - | - | - | - | 0.3 | 116.0 | 82.3 | 46.5 | - |
DPO |
1208.4 | 1488.1 | 787.6 | 2475.4 | 2150.1 | 2851.1 | 2037.9 | 1624.1 | 922.6 | 1001.5 | 1790.3 | 981.8 | - |
Operating Cycle |
91.1 | 4854.3 | 7912.5 | 0.8 | 2485.9 | 272.1 | 321.5 | 71.3 | 85.7 | 214.8 | 82.3 | 46.5 | - |
Cash Conversion Cycle |
-1117.3 | 3366.2 | 7124.9 | -2474.6 | 335.8 | -2579.0 | -1716.4 | -1552.8 | -836.9 | -786.6 | -1708.0 | -935.3 | - |
All numbers in USD currency
Quarterly Financial Ratios Lineage Cell Therapeutics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.02 | -0.03 | -0.04 | - | -0.04 | -0.03 | -0.03 | - | -0.04 | -0.04 | -0.04 | -0.17 | -0.05 | -0.03 | -0.01 | 0.01 | -0.05 | -0.04 | -0.06 | -0.03 | -0.11 | -0.2 | 0.3 | -0.36 | 0.53 | -0.03 | -0.5 | -0.58 | 0.12 | -0.11 | 0.46 | -0.05 | 0.3 | 0.26 | -0.19 | -0.16 | -0.18 | -0.12 | -0.13 | -0.14 | -0.12 | -0.16 | -0.14 | -0.35 | -0.16 | -0.14 | -0.15 | -0.12 | -0.1 | -0.11 | -0.1 | -0.1 | -0.08 | -0.09 | -0.07 |
EBITDA per Share |
-0.02 | -0.03 | -0.04 | - | -0.04 | -0.03 | -0.04 | - | 0.82 | 0.84 | -0.04 | -0.17 | -0.04 | -0.04 | -43.3 | -0.04 | -0.04 | -41.3 | -0.05 | -0.05 | -0.05 | -0.07 | -0.09 | -0.08 | -0.08 | -0.07 | -0.09 | -0.08 | -0.08 | -0.08 | -104 | -0.11 | -83.3 | -146 | -258 | -0.24 | -206 | -166 | -0.17 | -0.18 | -0.17 | -0.2 | -0.19 | -0.52 | -0.18 | -0.15 | -0.16 | -0.14 | -0.11 | -0.12 | -0.12 | -0.11 | -0.08 | -0.1 | -0.08 |
ROE % |
-32.72 | -38.80 | -37.71 | -24.34 | -32.16 | -29.32 | -30.28 | -24.45 | -55.88 | -54.60 | -50.18 | -43.10 | -9.55 | -11.08 | -13.98 | -21.46 | -27.54 | -34.09 | -53.90 | -10.37 | -55.13 | 30.59 | 52.68 | -49.84 | -45.33 | -107.63 | -110.31 | -12.28 | 27.75 | 45.40 | 73.38 | 28.57 | -19.56 | -96.69 | -153.54 | -176.84 | -153.51 | -125.51 | -115.59 | -100.00 | -203.52 | -241.67 | -266.56 | -296.50 | -226.98 | -217.88 | -223.81 | -223.54 | -178.49 | -139.81 | -97.81 | -57.65 | -13.05 | -14.93 | -11.74 |
ROA % |
-21.47 | -25.03 | -24.11 | -15.24 | -19.87 | -17.80 | -18.09 | -14.51 | -31.12 | -32.46 | -31.04 | -27.26 | -8.77 | -10.00 | -12.48 | -19.13 | -24.58 | -30.55 | -48.44 | -9.33 | -49.98 | 28.81 | 48.60 | -45.24 | -42.54 | -99.91 | -102.49 | -11.53 | 26.52 | 40.14 | 64.08 | 23.63 | 12.83 | -23.45 | -50.90 | -49.64 | -49.48 | -46.13 | -48.60 | -48.67 | -68.53 | -73.09 | -73.46 | -76.02 | -62.34 | -63.41 | -68.68 | -72.02 | -62.94 | -54.43 | -45.42 | -36.04 | -8.16 | -9.33 | -7.34 |
ROCE % |
- | - | - | - | -6.77 | -13.54 | -18.74 | -19.47 | -50.09 | -49.04 | -49.58 | -48.12 | -23.61 | -24.88 | -25.81 | -27.49 | -27.46 | -27.93 | -30.85 | -34.42 | -39.29 | -42.87 | -43.03 | -44.72 | -39.65 | -34.46 | -29.98 | -23.92 | -27.58 | -29.83 | -36.78 | -47.02 | -86.78 | -131.34 | -160.83 | -187.39 | -172.75 | -149.33 | -139.10 | -122.21 | -213.22 | -227.74 | -231.09 | -240.20 | -180.83 | -192.91 | -215.19 | -234.79 | -186.73 | -145.05 | -104.64 | -62.56 | -14.17 | -16.68 | -13.48 |
Current Ratio |
3.0 | 2.9 | 2.9 | 2.6 | 2.7 | 2.8 | 2.6 | 2.4 | 2.5 | 2.5 | 2.4 | 2.1 | 11.3 | 12.1 | 11.3 | 8.4 | 8.4 | 8.4 | 8.4 | 8.8 | 8.8 | 8.8 | 8.8 | 10.8 | 10.8 | 10.8 | 10.8 | 19.3 | 19.3 | 19.3 | 19.3 | 11.8 | 11.8 | 11.8 | 11.8 | 5.2 | 5.2 | 5.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
7.7 | 10.1 | 26.0 | - | 30.7 | 8.2 | 9.0 | - | 14.7 | 8.6 | 444.0 | 2061.0 | 42.6 | - | 28.2 | 62.2 | 19.3 | - | 3.9 | 1.6 | - | - | 2.5 | 3.1 | - | - | 9.1 | 6.7 | - | - | 40.2 | 14.2 | - | - | 16.6 | 49.5 | 23.9 | 26.1 | 41.7 | 30.1 | 42.1 | 45.3 | 48.1 | 31.5 | 73.6 | 43.2 | 72.1 | 33.8 | 35.9 | 34.9 | 52.3 | 19.7 | 28.2 | 21.3 | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.2 | - | 58.8 | 104.6 | 97.7 | - | 105.1 | 96.3 | 153.8 | - | 78.9 | 90.2 | 58.4 | - | 29.7 | 60.1 | 239.7 | - | 252.2 | 188.2 | - |
DPO |
4787.0 | 4768.9 | 1983.8 | - | 1246.5 | 1863.8 | 2068.1 | - | 1058.9 | 1176.7 | 1684.8 | - | 286.1 | 2013.7 | 2203.0 | - | 2335.8 | 3176.7 | 2445.3 | - | 1942.7 | 2069.8 | 3211.2 | - | 6150.2 | 2030.7 | 1380.0 | - | 1646.0 | 17118.5 | 2025.9 | - | 2506.2 | 1530.1 | 890.4 | - | 591.0 | 982.0 | 880.5 | - | 907.4 | 831.7 | 1982.3 | - | 1716.6 | 1962.1 | 1262.3 | - | 628.0 | 1270.1 | 5146.4 | - | 5510.2 | 2055.7 | - |
Operating Cycle |
7.7 | 10.1 | 26.0 | - | 30.7 | 8.2 | 9.0 | - | 14.7 | 8.6 | 444.0 | 2061.0 | 42.6 | - | 28.2 | 62.2 | 19.3 | - | 3.9 | 1.6 | - | - | 2.5 | 3.1 | - | - | 9.1 | 6.7 | - | - | 40.2 | 14.2 | - | - | 16.8 | 49.5 | 82.8 | 130.8 | 139.4 | 30.1 | 147.1 | 141.6 | 201.9 | 31.5 | 152.5 | 133.4 | 130.5 | 33.8 | 65.7 | 95.0 | 292.1 | 19.7 | 280.4 | 209.5 | - |
Cash Conversion Cycle |
-4779.3 | -4758.7 | -1957.8 | - | -1215.8 | -1855.6 | -2059.1 | - | -1044.2 | -1168.1 | -1240.8 | 2061.0 | -243.5 | -2013.7 | -2174.8 | 62.2 | -2316.5 | -3176.7 | -2441.4 | 1.6 | -1942.7 | -2069.8 | -3208.7 | 3.1 | -6150.2 | -2030.7 | -1371.0 | 6.7 | -1646.0 | -17118.5 | -1985.7 | 14.2 | -2506.2 | -1530.1 | -873.6 | 49.5 | -508.3 | -851.2 | -741.1 | 30.1 | -760.2 | -690.1 | -1780.4 | 31.5 | -1564.1 | -1828.8 | -1131.8 | 33.8 | -562.3 | -1175.1 | -4854.4 | 19.7 | -5229.9 | -1846.2 | - |
All numbers in USD currency